A failed phase III trial has Ipsen clutching at straws to salvage its rare bone disease project palovarotene, which it bought for $1bn a mere 11 months ago.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,